198 related articles for article (PubMed ID: 18723016)
1. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.
Politis M; Piccini P; Pavese N; Koh SB; Brooks DJ
Exp Neurol; 2008 Nov; 214(1):112-6. PubMed ID: 18723016
[TBL] [Abstract][Full Text] [Related]
2. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
3. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.
Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ
Brain; 2008 May; 131(Pt 5):1294-302. PubMed ID: 18362097
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
[TBL] [Abstract][Full Text] [Related]
5. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
6. [
Stark AJ; Smith CT; Petersen KJ; Trujillo P; van Wouwe NC; Donahue MJ; Kessler RM; Deutch AY; Zald DH; Claassen DO
Neuroimage Clin; 2018; 18():433-442. PubMed ID: 29541577
[TBL] [Abstract][Full Text] [Related]
7. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
9. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B
Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165
[TBL] [Abstract][Full Text] [Related]
10. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
[TBL] [Abstract][Full Text] [Related]
11. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
[TBL] [Abstract][Full Text] [Related]
12. Function of sigma1 receptors in Parkinson's disease.
Mishina M; Ishiwata K; Ishii K; Kitamura S; Kimura Y; Kawamura K; Oda K; Sasaki T; Sakayori O; Hamamoto M; Kobayashi S; Katayama Y
Acta Neurol Scand; 2005 Aug; 112(2):103-7. PubMed ID: 16008536
[TBL] [Abstract][Full Text] [Related]
13. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
14. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
15. Suite PET/CT neuroimaging for the diagnosis of Parkinson's disease: statistical parametric mapping analysis.
Wang R; Xu B; Guo Z; Chen T; Zhang J; Chen Y; Zhu H
Nucl Med Commun; 2017 Feb; 38(2):164-169. PubMed ID: 27893588
[TBL] [Abstract][Full Text] [Related]
16. Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study.
Strafella AP; Ko JH; Grant J; Fraraccio M; Monchi O
Eur J Neurosci; 2005 Dec; 22(11):2946-52. PubMed ID: 16324129
[TBL] [Abstract][Full Text] [Related]
17. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy.
Landvogt C; Buchholz HG; Bernedo V; Schreckenberger M; Werhahn KJ
Epilepsia; 2010 Sep; 51(9):1699-706. PubMed ID: 20384765
[TBL] [Abstract][Full Text] [Related]
18. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
19. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
[TBL] [Abstract][Full Text] [Related]
20. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
Politis M; Sauerbier A; Loane C; Pavese N; Martin A; Corcoran B; Brooks DJ; Ray-Chaudhuri K; Piccini P
Mov Disord; 2017 Feb; 32(2):235-240. PubMed ID: 27859651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
